Drugs / LY3873862
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05492201 | Aug 2022 → Apr 2025 | — | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3873862 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05492201 ↗ |
| Route | Oral | “Administered orally.” NCT05492201 ↗ |